U.S. Contraceptives Market Size

U.S. Contraceptives Market Size

U.S. contraceptives market size was valued at around USD 7 billion in 2023 and is expected to exhibit growth at a CAGR of 7.2% from 2024 to 2032. Contraceptives, also known as birth control methods, are various types of devices and drugs used to prevent pregnancy by intentionally inhibiting or reducing the chances of conception. The market encompasses a range of contraceptive methods, including condoms, IUDs, vaginal rings, pills, and more.

A prominent trend in the market is the growing preference for long-acting reversible contraceptives (LARCs), such as intrauterine devices (IUDs) and contraceptive implants. Additionally, hormonal contraceptives like oral contraceptive pills remain popular, though innovations such as non-hormonal gels are gaining traction, appealing to individuals who prefer non-hormonal options.
 

Another key trend is the expansion of over-the-counter (OTC) access to contraceptives. In 2023, the FDA approved Opill, a progestin-only oral contraceptive, for OTC sales—a move expected to improve accessibility, particularly for younger women and those in rural areas. This approval reflects a broader push for policy changes aimed at reducing barriers to contraception, aligning with efforts under the Affordable Care Act, which mandates insurance coverage for contraceptive methods without out-of-pocket costs.
 

Telemedicine platforms are also influencing the market, with companies like Nurx and Planned Parenthood Direct offering convenient mail-order birth control services, especially in the wake of the COVID-19 pandemic.
 

Meanwhile, the male contraceptive market is slowly emerging, with clinical trials for non-hormonal male contraceptives, such as the Vasalgel injection, showing promise, though widespread availability remains several years away. These trends indicate an evolving market that prioritizes accessibility, innovation, and diverse consumer preferences.